AstraZeneca has revealed that its top executive ... have involved cancer treatments Enhertu (trastuzumab deruxtecan), Imfinzi (durvalumab), or Imjudo (tremelimumab). Imfinzi was first approved ...

A spokesperson for AstraZeneca told pharmaphorum that the ... where AZ faces tough competition and its checkpoint inhibitors Imfinzi (durvalumab) and tremelimumab have failed to score the big ...